$20.03
1.68% yesterday
Nasdaq, May 20, 09:47 pm CET
ISIN
US7665596034
Symbol
RIGL
Sector
Industry

Rigel Pharmaceuticals, Inc. Stock price

$20.12
+3.19 18.84% 1M
-4.19 17.24% 6M
+3.30 19.62% YTD
+10.57 110.70% 1Y
+0.02 0.10% 3Y
+0.32 1.62% 5Y
-18.68 48.14% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.42 2.13%
ISIN
US7665596034
Symbol
RIGL
Sector
Industry

Key metrics

Market capitalization $359.59m
Enterprise Value $343.56m
P/E (TTM) P/E ratio 9.71
EV/FCF (TTM) EV/FCF 9.66
EV/Sales (TTM) EV/Sales 1.69
P/S ratio (TTM) P/S ratio 1.77
P/B ratio (TTM) P/B ratio 19.36
Revenue growth (TTM) Revenue growth 68.74%
Revenue (TTM) Revenue $203.08m
EBIT (operating result TTM) EBIT $43.93m
Free Cash Flow (TTM) Free Cash Flow $35.56m
Cash position $77.10m
EPS (TTM) EPS $2.07
P/E forward 9.64
P/S forward 1.66
EV/Sales forward 1.59
Short interest 10.64%
Show more

Is Rigel Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Rigel Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Rigel Pharmaceuticals, Inc. forecast:

2x Buy
33%
4x Hold
67%

Analyst Opinions

6 Analysts have issued a Rigel Pharmaceuticals, Inc. forecast:

Buy
33%
Hold
67%

Financial data from Rigel Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
203 203
69% 69%
100%
- Direct Costs 21 21
158% 158%
10%
182 182
62% 62%
90%
- Selling and Administrative Expenses 110 110
4% 4%
54%
- Research and Development Expense 26 26
26% 26%
13%
46 46
445% 445%
23%
- Depreciation and Amortization 2.43 2.43
88% 88%
1%
EBIT (Operating Income) EBIT 44 44
398% 398%
22%
Net Profit 37 37
288% 288%
18%

In millions USD.

Don't miss a Thing! We will send you all news about Rigel Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rigel Pharmaceuticals, Inc. Stock News

Positive
Seeking Alpha
13 days ago
Rigel Pharmaceuticals, Inc. shows strong momentum, with a 68% YoY revenue increase, driven by TAVALISSE, GAVRETO, and REZLIDHIA, suggesting a shift to a durable growth stock. Q1 net income of $11.4M and improved gross margins highlight Rigel's operating leverage, reducing the need for dilutive fundraising and supporting future R&D investments. R289's promising pipeline progress and TAVALISSE's ...
Neutral
Seeking Alpha
14 days ago
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Ray Furey - Executive Vice President, General Counsel & Corporate Secretary. Raul Rodriguez - President & Chief Executive Officer Dave Santos - Chief Commercial Officer Lisa Rojkjaer - Chief Medical Officer Dean Schorno - Chief Financial Officer Conference Call Participants Ka...
Neutral
PRNewsWire
14 days ago
First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 million Generated $11.4 million of net income in the first quarter of 2025 R289 granted Orphan Drug designation for the treatment of MDS and Fast Track designation for the treatment of previously-treated transfusion dependent lower-...
More Rigel Pharmaceuticals, Inc. News

Company Profile

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Head office United States
CEO Raul Rodriguez
Employees 164
Founded 1996
Website www.rigel.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today